This browser does not support the video element.
The Evidence for Aspirin - Visual Abstract Three new aspirin trials in three different populations: - ARRIVE - Moderate Risk (ASCVD > 20%) <-> MACE + Increased bleeding ASCEND - Diabetes <-> MACE ++ bleeding ASPREE - Age > 70 <-> MACE + bleeding + mortality #Aspirin #VisualAbstract #ARRIVE #ASCEND #ASPREE #Management #EBM #Trials